Johnson & Johnson (NYSE:JNJ) Trading Up 0.7%

Johnson & Johnson (NYSE:JNJ)’s stock price rose 0.7% on Monday . The stock traded as high as $165.36 and last traded at $165.36. Approximately 1,317,914 shares were traded during trading, a decline of 82% from the average daily volume of 7,265,850 shares. The stock had previously closed at $164.13.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a report on Tuesday, July 30th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 16th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Finally, TD Cowen decreased their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Trading Up 0.3 %

The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The stock has a 50-day moving average price of $153.92 and a 200-day moving average price of $153.20. The stock has a market cap of $396.26 billion, a P/E ratio of 10.26, a P/E/G ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter last year, the company posted $2.80 EPS. The business’s quarterly revenue was up 4.3% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.01%. Johnson & Johnson’s dividend payout ratio is 30.92%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Innealta Capital LLC bought a new stake in Johnson & Johnson in the second quarter valued at approximately $27,000. Christopher J. Hasenberg Inc bought a new stake in Johnson & Johnson in the 1st quarter worth $31,000. Vermillion & White Wealth Management Group LLC bought a new position in shares of Johnson & Johnson during the fourth quarter valued at about $44,000. Disciplined Equity Management Inc. bought a new stake in shares of Johnson & Johnson in the fourth quarter worth about $45,000. Finally, MFA Wealth Advisors LLC purchased a new position in Johnson & Johnson during the 2nd quarter valued at about $43,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.